Home Cart Sign in  
Chemical Structure| 24512-63-8 Chemical Structure| 24512-63-8

Structure of Geniposide
CAS No.: 24512-63-8

Chemical Structure| 24512-63-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Geniposide, a natural product isolated and purified from the fruit of Gardenia jasminoides Ellis., can induce increased activity of phase II detoxifying enzymes, inhibit tumor promotion, and induce apoptosis in rat C6 glioma cells. Geniposide can also be transformed to blue pigments by a simple modification, may be used as a value-added food colorant, and shows a greater protective effect on the granule cell layer than on the pyramidal cell layer including CA 1 and CA 3.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Geniposide

CAS No. :24512-63-8
Formula : C17H24O10
M.W : 388.37
SMILES Code : O=C(C1=CO[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)[C@@]3([H])[C@]1([H])CC=C3CO)OC
MDL No. :MFCD16036219

Safety of Geniposide

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HUVECs 200 μg/ml 24 hours Inhibited endothelial cell migration and tube formation but did not directly inhibit angiogenesis Br J Pharmacol. 2020 Jul;177(14):3240-3257
MHCC-97L cells 40 μg/ml 24 hours Inhibited VEGF transcription and secretion by suppressing TLR4/MyD88 pathway and STAT3/Sp1-dependent VEGF production Br J Pharmacol. 2020 Jul;177(14):3240-3257
PLC/PRF/5 cells 40 μg/ml 24 hours Inhibited VEGF transcription and secretion by suppressing TLR4/MyD88 pathway and STAT3/Sp1-dependent VEGF production Br J Pharmacol. 2020 Jul;177(14):3240-3257
Neonatal rat cardiomyocytes 100 μM 24 hours Geniposide suppressed hypertrophy by activating AMPK α, and knockdown of AMPK α abolished its protective effects. Br J Pharmacol. 2016 May;173(9):1502-16
H9c2 cardiomyocytes 100 μM 24 hours Geniposide inhibited the hypertrophic response induced by Ang II or isoprenaline, characterized by decreased ANP and CSA. Br J Pharmacol. 2016 May;173(9):1502-16
Caco-2 cells 25–100 μg/mL 12–48 hours Ameliorated LPS-induced endothelial barrier dysfunction by dose-dependently increasing transepithelial electrical resistance (TER) and up-regulating tight junction proteins (occludin and ZO-1) expression Acta Pharmacol Sin. 2017 May;38(5):688-698
human umbilical vein endothelial cells (HUVECs) 15µM 24 hours Inhibits HUVECs apoptosis, up-regulates the expression of the antiapoptotic protein Bcl-2 and down-regulates the expression of the proapoptotic protein BAX, inhibits the expression of Cleaved caspase-3. J Nanobiotechnology. 2024 Mar 25;22(1):129

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice Orthotopic HCC model Intragastric 30 mg/kg Twice daily for 5 weeks Inhibited HCC growth and lung metastasis by suppressing TLR4/MyD88 pathway and STAT3/Sp1-dependent VEGF production Br J Pharmacol. 2020 Jul;177(14):3240-3257
C57/B6 mice Transverse aortic constriction (TAC)-induced cardiac hypertrophy model Oral 25 or 50 mg/kg Once daily for 7 weeks Geniposide protected against cardiac hypertrophy via activation of the GLP-1 receptor/AMPK α pathway, improving cardiac function. Br J Pharmacol. 2016 May;173(9):1502-16
Sprague-Dawley (SD) rats TNBS-induced experimental colitis Intragastrically 25, 50 mg/kg Once daily for 14 consecutive days Ameliorated TNBS-induced experimental colitis and related symptoms, reduced inflammatory cytokine (TNF-α, IL-1β, IL-6) release and neutrophil infiltration (MPO activity), and modulated disrupted epithelial barrier function via activating the AMPK signaling pathway Acta Pharmacol Sin. 2017 May;38(5):688-698
ApoE−/− mice High-fat diet (HFD) induced atherosclerosis model Intravenous administration 5 mg/kg Once a week for 8 weeks Targets atherosclerotic plaques, reduces plaque area and ROS levels, restores endothelial cell function, promotes cholesterol outflow. J Nanobiotechnology. 2024 Mar 25;22(1):129

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.57mL

0.51mL

0.26mL

12.87mL

2.57mL

1.29mL

25.75mL

5.15mL

2.57mL

References

 

Historical Records

Categories